$3.5M grant to help Inovio further develop mass vaccine device

04/11/2013 | Genetic Engineering & Biotechnology News

The National Institute of Allergy and Infectious Diseases awarded Inovio Pharmaceuticals a $3.5 million grant to further develop a next-generation DNA vaccine delivery device that can simultaneously administer multiple synthetic vaccines through skin surface electroporation. The device is being co-developed with Chief Scientist Connie Schmaljohn of the Army Medical Research Institute of Infectious Diseases. The goal is to create a device that will allow fast vaccination of U.S. troops and protect the public from pandemic threats.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ